J. Robijns , S. Censabella , S. Claes , L. Pannekoeke , L. Bussé , D. Colson , I. Kaminski , A. Maes MD, P. Bulens , M. Brosens , L. Noé , I. Lambrichts , A. Timmermans , V. Somers , J. Mebis MD, PhD
J. Mebis MD, PhD, S. Censabella , S. Engels , G. Orye , S. Marquette , C. Van Narsenille , L. Vansteelant , Leen Noe , A. Maes MD, Paul Bulens , Daisy Luyten , E.J.R. Joosens
J. Mebis MD, PhD, S. Censabella , S. Engels , C. Van Narsenille , G. Orye , S. Marquette , L. Vansteelant , L. Noé , A. Maes MD, P. Bulens , E.J.R. Joosens , D. Luyten MD
J. Robijns , S. Censabella , P. Bulens , A. Maes MD, L. Noé , M. Brosens , L. Van den Bergh MD, PhD, S. Claes , J. Mebis MD, PhD
SUMMARY
Photobiomodulation therapy is based on the application of visible and/or (near-)infrared light on the target tissue. We performed a review of 34 articles on the use of photobiomodulation therapy in the management of cancer related lymphoedema, oral mucositis, radiodermatitis, chemotherapy-induced peripheral neuropathy, osteonecrosis of the jaw, and xerostomia/hyposalivation. The findings suggest that photobiomodulation therapy is a promising option for the management of these cancer therapy-related side effects.
Top
